Ani Pharmaceuticals (ANIP) Total Non-Current Liabilities (2011 - 2026)

Ani Pharmaceuticals has reported Total Non-Current Liabilities for 15 years, with the latest figure at $851.1 million in Q1 2026.

• Quarterly Total Non-Current Liabilities rose 1.08% year-over-year to $851.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $851.1 million (up 1.08% YoY) and the FY2025 annual result came in at $887.5 million, up 4.39% from the prior year.
• Total Non-Current Liabilities retreated to $851.1 million in Q1 2026 per ANIP's latest filing, from $887.5 million in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $894.3 million in Q3 2025 and troughed at $366.7 million in Q1 2022.
• A 5-year average of $600.5 million and a median of $429.9 million in 2023 frame the typical range for Total Non-Current Liabilities.
• The sharpest annual moves came in 2024 and 2025: Total Non-Current Liabilities climbed 0.47% in 2024, then surged 104.25% in 2025.
• Over 5 years, Total Non-Current Liabilities stood at $420.2 million in 2022, then rose by 5.2% to $442.0 million in 2023, then soared by 92.34% to $850.2 million in 2024, then gained by 4.39% to $887.5 million in 2025, then fell by 4.1% to $851.1 million in 2026.
• According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $851.1 million, $887.5 million, and $894.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.